Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. will unveil data from more than 20 studies at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD ...

Study over 24 weeks on patients with type 2 diabetes Says exenatide once-weekly shows superior glucose control Dec 15 (Reuters) - Amylin Pharmaceuticals Inc reported positive data from a study that ...

Amylin Pharmaceuticals, Inc. Eli Lilly and Company and Alkermes Inc. announced positive results from a phase II study evaluating the effects of a once-monthly injectable suspension formulation of ...

Appointment comes as Vivani prioritizes the development of its GLP-1 implants for the treatment of obesity and chronic weight management Under Bradbury’s leadership as CEO, Amylin Pharmaceuticals, ...

Amylin (and partners Eli Lilly and Alkermes) have submitted an application for a once-weekly version of its diabetes blockbuster Byetta to the regulators in the USA, a day after the company announced ...

(Sharecast News) - AstraZeneca announced on Thursday that the European Commission (EC) has approved Bydureon BCise - exenatide 2mg prolonged-release suspension for injection in pre-filled pen - as a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Previous studies suggest GLP-1 receptor agonists may ...

The co and Eli Lilly (LLY) announces the FDA has approved more convenient patient storage instructions for BYETTA (exenatide) injection. BYETTA Pens can now be kept at a room temperature not to exceed ...